Results 41 to 50 of about 307,775 (306)

Phase 1 dose escalation study of the allosteric AKT inhibitor BAY 1125976 in advanced solid cancer-Lack of association between activating AKT mutation and AKT inhibition-derived efficacy [PDF]

, 2019
This open-label, phase I first-in-human study (NCT01915576) of BAY 1125976, a highly specific and potent allosteric inhibitor of AKT1/2, aimed to evaluate the safety, pharmacokinetics, and maximum tolerated dose of BAY 1125976 in patients with advanced ...
Boix, Oliver, Hess, Dagmar, Hurvitz, Sara A, Joerger, Markus, Lagkadinou, Eleni, Ma, Cynthia, Moulder, Stacy, Ocker, Matthias, Rentzsch, Christine, Rudolph, Marion, Schneeweiss, Andreas, Thiele, Silke, Tsimberidou, Apostolia M, Varga, Andrea, Wilkinson, Gary   +14 more
core   +3 more sources

Preclinical evaluation of drugs to block inflammation-driven preterm birth [PDF]

Innate Immunity, 2016
Intrauterine inflammation, the major cause of early preterm birth, can have microbial and sterile aetiologies. We assessed in a Transwell model the anti-inflammatory efficacies of five drugs on human extraplacental membranes delivered after preterm spontaneous labour (30–34 wk).
Demelza J, Ireland, Elizabeth A, Nathan, Shaofu, Li, Adrian K, Charles, Lisa F, Stinson, Matthew W, Kemp, John P, Newnham, Jeffrey A, Keelan   +7 more
openaire   +2 more sources

Biomarker-Drug and Liquid Biopsy Co-development for Disease Staging and Targeted Therapy: Cornerstones for Alzheimer's Precision Medicine and Pharmacology. [PDF]

, 2019
Systems biology studies have demonstrated that different (epi)genetic and pathophysiological alterations may be mapped onto a single tumor's clinical phenotype thereby revealing commonalities shared by cancers with divergent phenotypes.
Goetzl, Edward J, Hampel, Harald, Kapogiannis, Dimitrios, Lista, Simone, Vergallo, Andrea   +4 more
core   +2 more sources

Biodistribution of AAV1, AAV5, AAV9, and AAVDJ serotypes after intra-cisterna magna delivery in non-human primates

Molecular Therapy: Methods & Clinical Development
Delivering drugs effectively to the central nervous system (CNS) is a major challenge in drug development, including adeno-associated virus (AAV) gene therapy.
Takuro Okai, Sho Sato, Hironobu Yasuno, Miyu Nakayama, Syunsuke Yamamoto, Sebastian Sjöqvist, Kentaro Otake, Masato Nakashima, Mugdha Deshpande, Elizabeth Galbreath, Jeong-Ho Oak, Saku Miyamoto, Gabriele Proetzel   +12 more
doaj   +1 more source

Combined Treatment with MEK and mTOR Inhibitors is Effective in In Vitro and In Vivo Models of Hepatocellular Carcinoma. [PDF]

, 2019
Background: Hepatocellular carcinoma (HCC) is the most common primary liver cancer histotype, characterized by high biological aggressiveness and scarce treatment options.
Calvisi, Diego F, Che, Li, Chen, Xin, Evert, Matthias, Hu, Junjie, Liu, Xianqiong, Lu, Xinjun, Song, Xinhua, Su, Tao, Utpatel, Kirsten, Wang, Jingxiao, Wang, Pan, Xu, Meng, Zhang, Jie, Zhang, Yi   +14 more
core   +1 more source

Hooking the big one: the potential of zebrafish xenotransplantation to reform cancer drug screening in the genomic era

Disease Models & Mechanisms, 2014
The current preclinical pipeline for drug discovery can be cumbersome and costly, which limits the number of compounds that can effectively be transitioned to use as therapies.
Chansey J. Veinotte, Graham Dellaire, Jason N. Berman   +2 more
doaj   +1 more source

Study protocol for THINK : a multinational open-label phase I study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour types [PDF]

, 2017
Introduction: NKR-2 are autologous T cells genetically modified to express a chimeric antigen receptor (CAR) comprising a fusion of the natural killer group 2D (NKG2D) receptor with the CD3 zeta signalling domain, which associates with the adaptor ...
Aftimos, Philippe, Awada, Ahmad, Brayer, Jason B, Catala, Gaetan, Davila, Marco L, Gilham, David E, Hendlisz, Alain, Kerre, Tessa, Lehmann, Frederic F, Lonez, Caroline, Machiels, Jean-Pascal H, Odunsi, Kunle, Piette, Fanny, Sallman, David A, Van den Neste, Eric, Verma, Bikash   +15 more
core   +1 more source

Replacement, Reduction, and Refinement of Animal Experiments in Anticancer Drug Development: The Contribution of 3D In Vitro Cancer Models in the Drug Efficacy Assessment

Biomedicines, 2023
In the last decades three-dimensional (3D) in vitro cancer models have been proposed as a bridge between bidimensional (2D) cell cultures and in vivo animal models, the gold standards in the preclinical assessment of anticancer drug efficacy. 3D in vitro
Elena M. Tosca, Davide Ronchi, Daniele Facciolo, Paolo Magni   +3 more
doaj   +1 more source

EXPERT EVALUATION OF PRECLINICAL STUDIES OF PRIMARY AND SECONDARY PHARMACODYNAMICS OF MEDICINES

Регуляторные исследования и экспертиза лекарственных средств, 2018
The article dwells upon the results of comparative analysis of the Russian national requirements  and EAEU regulations dealing with evaluation of preclinical pharmacological studies.
G. N. Engalycheva, R. D. Subaev, D. V. Gorachev, Yu. V. Olefir   +3 more
doaj   +1 more source

L-Tetrahydropalamatine: A Potential New Medication for the Treatment of Cocaine Addiction [PDF]

, 2012
Levo-tetrahydropalmatine (l-THP) is an active constituent of herbal preparations containing plant species of the genera Stephania and Corydalis and has been approved and used in China for a number of clinical indications under the drug name Rotundine ...
Mantsch, John R., Wang​, Jia Bei
core   +1 more source